CoChat

Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.

Jett, J R, Maksymiuk, A W, Su, J Q, Mailliard, J A, Krook, J E, Tschetter, L K, Kardinal, C G, Twito, D I, Levitt, R, Gerstner, J B · 1994 · Journal of Clinical Oncology
Cited by 117

The DOI matches its Crossref record.

Abstract

PURPOSE: We evaluated the effect of recombinant interferon gamma (rIFN-gamma) on survival and toxicity in small-cell lung cancer (SCLC) patients in complete remission (CR). PATIENTS AND METHODS: One hundred patients in CR following treatment with six cycles of combination chemotherapy, thoracic radiotherapy (TRT), and prophylactic cranial irradiation (PCI) were studied. All patients had been enrolled onto a cooperative group trial (North Central Cancer Treatment Group [NCCTG] 86-20-51). Patients received observation only or rIFN-gamma at a dose of 4 x 10(6) U subcutaneously per day for 6 months. RESULTS: Six patients (12%) did not comply with rIFN-gamma treatment. Substantial nonhematologic toxicities consisting of chills, myalgia, lethargy, and alteration of mood-personality were observed. No patient experienced life-threatening or fatal toxicity. The median times to progression for rIFN-gamma treatment or observation were 6.9 and 8.1 months (P = .54). The median survival times were 13.3 and 18.8 months, respectively (P = .43). Approximately 70% of all patients relapsed within 2 years. CONCLUSION: Time to progression and survival were inferior in patients treated with rIFN-gamma compared with randomized control subjects, although this difference was not statistically significant. These data indicate that rIFN-gamma treatment is not associated with a 33% improvement in survival (P = .04). Because of the high rate of relapse, SCLC patients in CR are an ideal group in which to evaluate novel and minimally toxic agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1994.12.11.2321

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 117

Metadata

Authors
Jett, J. R., Maksymiuk, A. W., Su, J. Q., Mailliard, J. A., Krook, J. E., Tschetter, L. K., Kardinal, C. G., Twito, D. I., Levitt, R., & Gerstner, J. B.
Venue
Journal of Clinical Oncology
Published
1994-11
Volume
12
Issue
11
Pages
2321-2326
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2253216568
Cited by
117
References
0
FWCI
1.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. https://app.cochat.ai/papers/10.1200/jco.1994.12.11.2321
The paper
Jett, J. R., Maksymiuk, A. W., Su, J. Q., Mailliard, J. A., Krook, J. E., Tschetter, L. K., Kardinal, C. G., Twito, D. I., Levitt, R., & Gerstner, J. B. (1994). Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.11.2321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.